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(2015), http://dx.doi.org/10.1016/j.Summary Objectives: HIV-1 patients show increased platelet activation, but the mecha-
nisms involved are not completely clarified. We speculated that HIV-1 might induce in vivo
platelet activation by enhancing platelet NOX2-related oxidative stress.
Methods: We measured soluble CD40 Ligand (sCD40L), a systemic marker of platelet activa-
tion, in 36 HIV-1 patients under effective combined antiretroviral therapy (cART) and in 10
na€ıve HIV-1 subjects. As control, 20 healthy subjects (HS) were included. Platelet oxidative
stress was measured by platelet NOX2-derived peptide (sNOX2-dp), p47phox translocation to
platelet membrane and platelet prostaglandin F2a (8-iso-PGF2a).
Results: sCD40L was increased both in HIV-1 na€ıve and cART patients compared to HS
(p < 0.001). Platelet sNOX2-dp and 8-iso-PGF2a were significantly higher in HIV-1 na€ıve subjects
compared to those on cART and to HS, and both were mutually correlated (R Z 0.734,
p < 0.001). A stepwise multivariable linear regression analysis showed that platelet sNOX2-
dp (b: 0.803, p < 0.001), HIV-1 infection (b: 0.146, p Z 0.014) and age (b: 0.166,
p Z 0.001) were independently associated to sCD40L levels.
Conclusions: HIV-1 infection is associated with increased platelet oxidative stress, which wasdeficiency Syndrome; cART, combined antiretroviral therapy; HIV-1, Human Immunodeficiency Virus
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(2015), http://dx.doi.org/10.1016/j.related to the activation of NOX2. The independent association between platelet NOX2 activa-
tion and plasma levels of sCD40L suggest that in vivo platelet activation may be dependent
upon platelet oxidative stress.
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114Introduction
The use of effective combined antiretroviral therapy (cART)
have progressively lengthened the survival of patients with
Human Immunodeficiency Virus type 1 (HIV-1) infection and
dramatically reduced the disease progression to full-blown
Acquired Immunodeficiency Syndrome (AIDS).1 Prolonged
life expectancy revealed a previously unrecognized risk of
developing cardiovascular (CV) diseases in HIV-1 patients,
with an accelerated atherosclerosis,2,3 increased coronary
heart disease and atherosclerotic plaque vulnerability.4,5
Ischemic complications may include not only coronary,
but also cerebrovascular disease, affecting intracranial ves-
sels and leading to progressive neurological and cognitive
impairment.6,7
Platelet activation play a crucial role on the onset of
atherosclerotic complications,8 and recent evidences sug-
gest that patients with HIV-1 infection disclose an enhanced
platelet activation.9
Nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase is a key enzyme involved in reactive oxygen species
(ROS) production.10 NADPH oxidase, which was well defined
in phagocytic cells, is composed of plasma membrane-
bound subunits (gp91phox/NOX2 and p22phox) and several
cytosolic subunits.11 Assembly of the cytosolic subunits
with NOX2 leads to enzyme activation and ROS production.
Upon activation, NOX2 releases a soluble peptide (sNOX2-
dp), which is a direct expression of the enzyme
activation.12
NOX2 was identified in platelets13 and its activation was
recognized to be a fundamental step in the formation of
platelet prostaglandin F2a (8-iso-PGF2a) in response to cell
agonists, arachidonic acid in particular.14,15 NOX2 activa-
tion is also a critical step for the release of pro-
thrombotic molecules such as soluble CD40L (sCD40L),10,13
indicating that NOX2 may be implicated on in vivo platelet
activation. Indeed, sCD40L has been proposed as a reliable
marker of platelet activation.16
Therefore, we speculated that NOX2 activity is up-
regulated in platelets from HIV-1 patients, so contributing
to in vivo platelet activation.
Thus, aim of our study is to investigate the behavior of
platelet activation and its interaction with platelet NOX2 in
HIV-patients.115
116
117
118
119
120
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123
124Materials and methods
Patients
Forty-six HIV-1 infected patients were enrolled. Subjects
were followed in an outpatient basis at the Department of
Clinical Medicine, “Sapienza” University of Rome. Thirty-six
patients were included according to the following criteria:stori D, et al., HIV-1 induces in viv
jinf.2015.01.005diagnosis of HIV-1 infection at any stage; effective cART
with a viral load <37 copies/mL from at least 12 months;
age >18 years; absence of severe obesity, arterial hyper-
tension, diabetes mellitus, and dyslipidemia. Patients with
an active opportunistic infection were excluded.
HIV-1 patients were treated with cART according to
current guidelines.17 Medication compliance was assessed
with regular drug refill.
Another group of 10 na€ıve HIV-1 patients with similar
demographic and clinical characteristics was enrolled. As
control, 20 healthy subjects (HS) from the same geographic
area matched for sex and age were included.
The study was approved by local ethic committee and
conducted according to the principles of the Declaration of
Helsinki.18 All enrolled subjects gave their written informed
consent.
Platelet preparation
Blood samples were obtained after a 12-h fast between
8.00 and 9.00 a.m. from subjects underwent routine
biochemical analysis including total cholesterol and
glucose. Samples, obtained from healthy subjects after su-
pine rest for at least 10 min, were taken into tubes with
3.8% sodium citrate. To acquire platelet-rich plasma
(PRP), samples were centrifuged for 15 min at 180 g. In or-
der to avoid leukocyte contamination, only the top 75% of
the PRP was collected according to Pignatelli et al.12
Platelet pellets were obtained by double centrifugation
(5 min, 300 g) of PRPs. Acid/citrate/dextrose (ACD) (1:7
v/v) was added to avoid platelet activation during process-
ing. Samples were suspended in HEPES buffer in presence of
0.1% albumin, pH 7.35. Platelet concentration in samples
used for in vitro experiments was adjusted at
2  105 platelets/mL. Cells were activated with Arachi-
donic Acid (0.5 mM) for 10 min at 37 C, separated from
the supernatant by centrifugation (5 min, 300 g) and the
two fractions, cells and supernatants, were stored at
80 C until analysis. All materials used were from Sigma
Aldrich unless otherwise specified.
Plasma soluble CD40L
Plasma levels of soluble CD40L (sCD40L) were measured
with a commercial immunoassay (Tema Ricerca, Bologna,
Italy). Values were expressed as ng/ml/2 105platelets.
Intra-assay and inter-assay coefficients of variation were
5% and 7% respectively. The detection limits is 0.16 ng/ml.
Analysis of platelet sNOX2-dp
Extracellular levels of soluble NOX2-derived peptide
(sNOX2-dp), were detected by an ELISA method as previ-
ously described by Pignatelli et al.12 in the supernatant ofo platelet activation by enhancing platelet NOX2 activity, J Infect
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YJINF3463_proof ■ 20 January 2015 ■ 3/8platelet suspension. The peptide was recognized by the
specific monoclonal antibody against the amino acidic
sequence of the extra membrane portion of NOX2 (catalytic
core of NADPH oxidase), which was released in the medium
upon platelet activation with AA.12 Values were expressed
as pg/ml/2 105platelets; intra-assay and inter-assay coef-
ficients of variation were 5.2% and 6%, respectively.
Platelet isoprostanes
Prostaglandin F2a (8-iso-PGF2a) was measured by a previ-
ously described and validated enzyme immunoassay
method19,20 in the supernatant of platelet suspension. 8-
iso-PGF2a values were expressed pmol/L/2 105platelets.
Intra-assay and inter-assay coefficients of variation were
4.4% and 8.8%, respectively.
Membrane and cytoplasmic protein extraction
Briefly, the extraction of membrane and cytoplasmic pro-
teins was performed by using the Proteo JETTM Membrane
Protein Extraction Kit (Fermentas International Inc, Mary-
land, USA) as reported by Fortu~no et al.21
Western blot analysis of p47phox
Platelets from patients who were evaluated for p47phox
translocation were analyzed immediately after the blood
sample collection. Platelets were suspended in a 2 Lysis
buffer (5 mM EDTA, 0.15 mol NaCl, 0.1 mol Tris pH 8.0,
1% triton and protease inhibitor cocktail). Equal amounts
of protein (30 mg/lane) estimated by Bradford assay were
solubilized in a 2 Laemmli buffer containing 2-
mercaptoethanol and loaded in a denaturing SDS/10% poly-
acrylamide gel. Western blot analysis was performed with
monoclonal anti-p47phox (Santa Cruz Biotechnology, Dallas,
USA) (1 mg/ml) incubated overnight at 4 C. Immune com-
plexes were detected by enhanced chemiluminescence.
The developed spots were calculated by densitometric
analysis on a NIHimage 1.62f analyzer and the values
were expressed in arbitrary unit (AU).
In particular, we removed from the densitometric
analysis the aspecific spot, and the values were expressed
as the ratio between the absolute values of the membranes
spots divided to absolute values of the corresponding
cytosolic spots (Densitometric Analysis of Membrane
Spots  Densitometric Analysis of Aspecific Spots/Densito-
metric Analysis of Cytosol Spots  Densitometric Analysis of
Aspecific Spots).
Statistical analysis
Categorical variables were reported as counts (percent-
ages) and continuous variables as means  standard devi-
ation (SD) or median and interquartile range (IQR) unless
otherwise indicated. Independence of categorical variables
was tested by c2 test. Normal distribution of parameters
was assessed by KolmogoroveSmirnov test.
Student unpaired t test and Pearson productemoment
correlation analysis were used for normally distributed
continuous variables. Group comparisons were performedPlease cite this article in press as: Pastori D, et al., HIV-1 induces in viv
(2015), http://dx.doi.org/10.1016/j.jinf.2015.01.005using analysis of variance (ANOVA). Appropriate nonpara-
metric tests (ManneWhitney U test, KruskaleWallis test,
Spearman rank correlation test) were employed for all
the other variables. Stepwise multivariable linear regres-
sion analysis was used to assess factors influencing
sCD40L. Only p values lower than 0.05 were considered as
statistically significant. All tests were two-tailed and ana-
lyses were performed using computer software packages
(SPSS-18.0, SPSS Inc.).
Sample size
On the basis of the results from a previous work on healthy
subjects,22 we calculated that a minimum of 10 patients
per group were required to have a 90% chance of detecting,
as significant at the 5% level, a difference for platelet NOX2
between groups of 6 pg/ml with SD Z 4 pg/ml.
Results
Clinical and biochemical characteristics
Table 1 reports clinical characteristics of healthy subjects
(HS), HIV-1 na€ıve subjects, and HIV-1 subjects on cART.
No differences on age, systolic and diastolic blood pressure,
BMI, fasting blood glucose, total cholesterol, platelet count
and smoking were present among groups. None of patients
or controls was receiving a treatment with antiplatelet
drugs or statins at baseline.
Antiretroviral agents
HIV-1 patients on cART were receiving non-nucleoside
reverse transcriptase inhibitor (NNRTI) e or protease inhib-
itor (PI)-based regimens (23 and 13 patients, respectively),
both in association with a nucleos(t)ide reverse transcrip-
tase inhibitor (NRTI) fixed-dose combination (lamivudine/
zidovudine or emtricitabine/tenofovir difumarate). Median
length of cARTwas 136.2 [84.4e204.1] months, and nadir of
CD4þ T cells was 269.9  131.3 cells/ml. There was no dif-
ference in the length of cART between the group with
NNRTI-based and PI-based cART (124.8 [91.6e183.3] vs.
164.0 [28.4e214.9] months, p Z 0.829). HIV-1 patients
receiving cART had higher values of CD4þ T lymphocytes
compared to HIV-1 na€ıve subjects (CD4% 34.0  11.9 vs.
23.5  6.3, p Z 0.011; CD4þ T absolute numbers
786.9  354.6 vs. 507.8  390.9 cells/ml, p Z 0.037). Viral
load was undetectable in all HIV-1 cART treated patients,
whereas among HIV-1 na€ıve subjects, median value of viral
load was 1711.0 copies/ml [IQR 129.2e8191.5].
Platelet activation and oxidative stress
Platelet activation
After stimulation with AA, HIV-1 subjects showed increased
values of sCD40L (21.1  5.8 vs. 12.6  3.3 ng/ml,
p < 0.001) compared to HS (Fig. 1). When we analyzed
separately HIV-1 na€ıve subjects and HIV-1 subjects on
cART, we found an increased level of sCD40L in na€ıve HIV-
1 infected group (25.9  4.12 ng/ml), compared to the
cART one (19.7  5.57 ng/ml, p Z 0.002) (Fig. 1).o platelet activation by enhancing platelet NOX2 activity, J Infect
Table 1 Demographic characteristics of seronegative and seropositive subjects.
HIV-1 negative (n Z 20) HIV-1 cART group (n Z 36) HIV-1 na€ıve subjects (n Z 10) p valuea
Age (years) 37.4  12.2 42.6  7.0 43.7  8.6 0.091
Female (n/%) 12 (60.0%) 11 (30.6%) 5 (50.0%) 0.089
High (cm) 169.4  10.8 172.9  8.3 168.8  7.1 0.263
Weight (kg) 64.6  9.9 68.9  10.5 63.8  11.5 0.215
Body Mass Index (kg/m2) 22.6  3.2 23.1  2.5 22.2  3.0 0.659
Fasting blood glucose (mg/dl) 86.7  9.0 83.3  9.2 81.9  7.7 0.656
Total cholesterol (mg/dl) 185.1  17.5 188.1  51.3 160.7  44.8 0.133
Platelet count (103/ml) 201.7  17.6 189.8  43.1 191.8  12.9 0.447
Smoking (%) 45.0 51.4 60.0 0.736
Systolic blood pressure (mmHg) 111.4  9.7 107.9  7.0 107.5  5.4 0.232
Diastolic blood pressure (mmHg) 66.4  6.3 68.3  7.3 71.0  5.7 0.225
cART: combined antiretroviral therapy.
a ANOVA.
Figure 1 Markers of platelet activation: box and whiskers
plots (median, interquartile range) of platelet activation, as-
sessed by plasma sCD40L levels in Healthy Subjects, HIV-1 cART
group, and HIV-1 na€ıve subjects.
Figure 2 Platelet oxidative stress: box and whiskers plots
(median and interquartile range) of platelet sNOX2-dp (Panel
A) and platelet 8-iso-PGF2a (Panel B) levels in Healthy Sub-
€
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Analysis of unstimulated platelets showed that oxidative
stress from HIV-1 subjects was higher compared HS. Thus,
we found that platelet sNOX2-dp and 8-iso-PGF2a levels
were significantly higher in HIV-1 na€ıve and HIV-1 cART sub-
jects compared to HS (Fig. 2, Panels A and B).
After stimulation with AA, platelet sNOX2-dp (23.5  7.6
vs. 14.8  3.8 pg/ml, p < 0.001), and platelet 8-iso-PGF2a
(148.9  47.9 vs. 120.8  16.8 pmol/l, p Z 0.001) from
HIV-1 subjects were higher compared to HS. Moreover,
HIV-1 na€ıve patients disclosed higher platelet sNOX2-dp
values (31.7  5.4 pg/ml), compared to patients under
cART (21.2  6.5 pg/ml p < 0.001, Fig. 2 Panel A).
Similarly values of platelet 8-iso-PGF2a were significantly
increased in HIV-1 na€ıve patients (184.3  28.4 pmol/l)
compared to those on cART (139.0  47.8 pmol/l,
p Z 0.001, Fig. 2 Panel B).
Platelet 8-iso-PGF2a and sNOX2-dp levels were highly
correlated (R Z 0.734, p < 0.001).
A sub analysis showed a significant difference in platelet
oxidative stress between HIV-1 patients treated with PI andPlease cite this article in press as: Pastori D, et al., HIV-1 induces in viv
(2015), http://dx.doi.org/10.1016/j.jinf.2015.01.005those treated with NNRTI (Table 2), both for platelet
sNOX2-dp (p Z 0.015) and platelet 8-iso-PGF2a
(p Z 0.018). In addition, patients treated with PI showed
increased values of sCD40L, compared to those on NNRTI
(p Z 0.009). Compared to HS, both the PI and NNRTI group
showed higher values of sCD40L and sNOX2-dp, whilstjects, HIV-1 cART group, and HIV-1 naıve subjects. 124
o platelet activation by enhancing platelet NOX2 activity, J Infect
Table 2 Differences of platelet activation and oxidative stress in AA-stimulated platelets between Healthy Subjects and HIV-1
patients according to the different cART regimens.
Healthy Subjects HIV-1 cART p valuea HIV-1 cART p valuea PI vs. NNRTI
PI-group NNRTI-group
sCD40L (ng/ml) 12.6  3.3 22.5  3.6 <0.001 18.2  5.9 0.001 0.009
Platelet sNOX2-dp (pg/ml) 14.8  3.8 24.2  4.0 <0.001 19.5  7.1 0.010 0.015
Platelet 8-iso-PGF2a (pmol/l) 120.8  16.8 162.8  40.3 <0.001 125.6  47.1 0.657 0.018
cART: combined antiretroviral therapy, PI: protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
a vs. Healthy Subjects.
Platelet activation in HIV-1 infection 5
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similar to those of HS (Table 2).78
79
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87Determinants of sCD40L levels
Table 3 reports correlations of sCD40L levels with selected
variables. We also performed a multivariable linear regres-
sion analysis which showed that platelet sNOX2-dp (b:
0.803, 95%CI 0.576e0.763, p < 0.001), HIV-1 infection (b:
0.146, 95%CI 0.427e3.675, p Z 0.014) and age (b: 0.166,
95%CI 0.046e0.185, pZ 0.001) were independently associ-
ated to sCD40L levels (adjusted R2:0.85).88
89
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To further investigate the mechanism underlying NOX2 up-
regulation, we measured AA-induced platelet p47phox trans-
location to cell membrane. We used AA as we previously
demonstrated that AA directly induces p47phox activation
and translocation to platelet membrane.12 We observed
that AA is able to increase the translocation of p47phox to
platelet membrane compared to unstimulated platelets,
with consequent decrease in the content of the cytosolic
fraction (Fig. 3, Panel C).
Western blot analysis showed that membrane levels of
p47phox were increased in HIV-1 infected patients compared
to HS (13.4  3.7 vs. 27.0  10.4 AU, p < 0.001) (Fig. 3,
Panels A and B).
Among HIV-1 patients, na€ıve subjects showed increased
value of p47phox compared to those on cART (41.9  7.1 vs.
22.9  6.7 AU, p < 0.001), and in na€ıve subjects (vs. cART
group), compared to HS (Fig. 3, Panel A). P47phox mem-
brane translocation was significantly associated to NOX2
activation (R Z 0.806, p < 0.001).Table 3 Correlations of factors associated to sCD40L levels.
Presence of HIV-1 infection
Length of cART
Age (years)
Body mass index
Smoking habit
Platelet sNOX2-dp (pg/ml)
Platelet 8-iso-PGF2a (pmol/l)
a Spearman correlation.
Please cite this article in press as: Pastori D, et al., HIV-1 induces in viv
(2015), http://dx.doi.org/10.1016/j.jinf.2015.01.005Discussion
Results from our study provide evidence that HIV-1 infec-
tion is associated with in vivo platelet activation and
suggest platelet NOX2 up-regulation as a potential under-
lying mechanism.
Patients with HIV-1 infection are characterized by
accelerated atherosclerosis4 and platelet activation is
believed to play a major role.9 A direct interplay between
HIV-1 and platelets may be implicated in platelet activa-
tion.23 Thus, platelets have been shown to possess recep-
tors for viruses, including HIV-1,24 and to be able to
internalize HIV-1 acting as phagocytes.25,26 Furthermore,
a relationship between virus replication and platelet acti-
vation has been demonstrated.23,27,28 However, the mecha-
nism potentially accounting for platelet activation in HIV-1
subjects it is still undefined.
Previous studies reported that HIV-1 structural and
functional proteins may promote NADPH oxidase activation
in different cell lines.29e31 This finding is of particular inter-
est in the context of platelet function as NADPH oxidase
play a relevant role in the process of platelet activation.13
Thus, studies from our group demonstrated that platelet
express this enzyme,13 which, upon activation, is impli-
cated in the mechanism of platelet activation via formation
of isoprostanes, a chemically stable eicosanoids with pro-
aggregating properties.14 Accordingly, patients with up-
regulation of the enzyme disclose platelet activation coin-
cidentally with platelet ROS formation and isoprostanes
over-production.10
In our study, platelets from HIV-1 subjects show
enhanced NOX2 activity, as depicted by higher levels of
platelet sNOX2-dp. Consistently with this finding platelet 8-
iso-PGF2a was higher in HIV-1 patients, especially in HIV-1R p value
0.604 <0.001
0.164a 0.347
0.296 0.016
0.031 0.804
0.059 0.640
0.897 <0.001
0.707 <0.001
111
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o platelet activation by enhancing platelet NOX2 activity, J Infect
Figure 3 Densitometry evaluation of the membrane p47phox content in platelets of Healthy Subjects, HIV-1 cART group and HIV-1
na€ıve (Panel A). A representative Western blot analysis of the membrane and cytosol p47phox content in Healthy Subjects (nZ 5),
HIV-1 cART group (nZ 5) and HIV-1 na€ıve (nZ 5) (Panel B). Western blot analysis of the membrane and cytosol p47phox content in
HIV-1 na€ıve (n Z 2) (Panel C).
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YJINF3463_proof ■ 20 January 2015 ■ 6/8na€ıve subjects, compared to HS. Platelet 8-iso-PGF2a was
highly correlated to sNOX2-dp, confirming, also in this
setting, the strong relationship between NOX2 activation
and isoprostanes formation. The increased level of isopros-
tanes is in accordance with previous data reporting
increased plasma 8-iso-PGF2a levels in HIV-1 patients in as-
sociation with viral replication.32,33 Together these data
show enhanced NOX2-derived oxidative stress in HIV-1,
which is dependent upon the viral replication in the blood.
To further substantiate the role of NOX2 in enhancing
platelet oxidative stress, we also performed an in vitro
study in which we analyzed translocation of the cytosolic
p47phox to platelet membrane NOX2. The role of this sub-
unit in NOX2 regulation is evident since subjects with the
hereditary deficiency of p47phox showed lower sNOX2-dp
level.34 HIV-1 patients showed significant increase of mem-
brane translocation of the p47phox in association with
enhanced sNOX2dp levels. Furthermore, p47phox was more
expressed in HIV-1 na€ıve subjects compared to those
receiving cART suggesting a role for viral replication in fa-
voring platelet NOX2 activation.
The results so far reported may provide a mechanistic
insight into the increase of in vivo platelet activation
detected in HIV-1 patients. Thus, plasma sCD40L, an
established marker of platelet activation35 was morePlease cite this article in press as: Pastori D, et al., HIV-1 induces in viv
(2015), http://dx.doi.org/10.1016/j.jinf.2015.01.005elevated in HIV-1 subjects compared to HS and significantly
correlated with NOX2 regulation, indicating a role for
NOX2-derived oxidative stress in eliciting in vivo platelet
activation.
Another important finding of our study is that, despite
being on effective cART, HIV-1 patients still showed an
increased platelet oxidative stress. This was demonstrated
by the residual significant difference, in platelet sNOX2-dp
and 8-iso-PGF2a, between HIV-1 subjects under cART and
seronegative subjects. This result may be attributable to
the persistence of a minimal residual viral load, responsible
for the persistent immune activation and chronic inflamma-
tion.36 However, we cannot exclude that antiretroviral
agents per se may induce in vivo platelet activation.37,38
Thus, analyzing the different antiretroviral treatment, we
found that patients treated with protease inhibitors showed
enhanced platelet oxidative stress and platelet activation
compared to patients on non-nucleoside reverse transcrip-
tase inhibitor-based regimens. This finding suggests that an-
tiretroviral agents may have different impact on platelet
function.
An implication of the study is that inhibition of NOX2
may represent a target to inhibit platelet activation in HIV-
1 patients. In this context, statins may be an interesting
option as this drug category is able to down regulate124
o platelet activation by enhancing platelet NOX2 activity, J Infect
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YJINF3463_proof ■ 20 January 2015 ■ 7/8NOX2.39 Small sample size is a limitation of the study, as it
does not allow conclusive data on the role of HIV-1 and
different antiretroviral agents on platelet function. In
particular, we could not exclude that different impact of
cART on platelet function and NOX activity might be medi-
ated by modulation of platelet levels of cyclic AMP.
In conclusion, oxidative stress-mediated platelet activa-
tion may represent a mechanism potentially responsible for
in vivo platelet activation in HIV-1 patients. Antiplatelet
treatment including NOX inhibition,38 in addition to effec-
tive cART, may be an useful approach for the prevention
of CV complications during HIV-1 infection.
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